{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:56:03Z","timestamp":1791276963946,"version":"4.1.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Right ventricular (RV) dysfunction (RVD) represents a power independent prognostic factor in patients with chronic heart failure (CHF); poor evidence exists about the effect of current guideline directed medical therapy on RVD. We investigated whether dapagliflozin improves right ventricular function, right ventricular\u2013pulmonary arterial coupling and pulmonary artery systolic pressure compared with standard therapy in CHF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a prospective observational registry with propensity score analysis investigating RV function and right heart failure (RIVED), focused on the effects of Dapagliflozin. Efficacy measures were intra and inter-groups changes from baseline to 6 months in RV end diastolic diameter (RVEDD), tricuspid annular peak systolic excursion (TAPSE), RV global longitudinal strain (RVGLS), fractional area changes (FAC), RV systolic tissue doppler wave (S\u2019), PASP values, TAPSE\/PASP, and tricuspid regurgitation (TR). Secondary endpoints were N-terminal pro B-type natriuretic peptide (NTproBNP) levels changes and combined adverse events rate of mortality and hospitalization at 180 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final population analysed was of 142 patients, in a balanced dataset consisting of 71 treated with standard HF therapy plus dapagliflozin (Dapa group) and 71 treated with standard therapy without dapagliflozin (control group).Median age was 78 [75\u201384] years old and 62% of patients were men. Patients in dapa group were younger [76 (66\u201382) vs 82 (74\u201388) years old; P &amp;lt; .001] and more frequently affected by diabetes mellitus (44% vs 22%; P = .002) compared with control group. No significant differences were observed between the two groups in terms of gender, renal function, NTproBNP and NYHA class. Over the 6 months follow-up, the Dapa group showed a significant improvement of RV function compared with controls (TAPSE +1.03\u2005mm, P &amp;lt; .001 and S\u2019 +0.48\u2005cm\/s, P = .006); whereas no significant differences between-groups were observed for FAC (P = .16). RV GLS at follow-up was significantly improved in the Dapagliflozin group compared with controls (adjusted mean difference \u22121.54%, P &amp;lt; .001) as well as of the pulmonary-arterial coupling (TAPSE\/PASP adjusted differences ranging from +0.07 to +0.17, P = .025). In patients with PH, a significant decrease in PASP [30 (25\u201334) vs 37 (31\u201345) mmHg, P &amp;lt; .001] associated with a RVGLS significant improvement [\u221220 (\u221222 to \u221219) vs \u221219 (\u221220 to \u221217) P &amp;lt; .001] in the Dapagliflozin group were observed. TAPSE\/PASP ratio was significantly improved in Dapagliflozin group with respect to the control group [0.67 (052\u20130.78) vs 0.51 (0.42\u20130.61), P &amp;lt; .001]. Secondary endpoints analysis revealed that NT-proBNP levels were significantly improved from baseline to follow-up only in dapaglifozin group (from 938 to 726\u2005pg\/mL P = .013). The rate of 180-days adverse events was significantly higher in control group with respect to Dapaglifozin group (21% vs 8%, P &amp;lt; .01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real-world HF cohort, dapagliflozin was associated with improved RV morphology and function, lower PASP, and better RV\u2013PA coupling, suggesting a direct haemodynamic and RV-targeted benefit beyond LV remodelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>(ClinicalTrials.gov Identifier: NCT06002321)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag230","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:01:26Z","timestamp":1788296486000},"source":"Crossref","is-referenced-by-count":0,"title":["Dapagliflozin effects on right ventricular function, pulmonary pressure and coupling: a propensity score analysis from the RIVED-HF"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6235-984X","authenticated-orcid":false,"given":"Alberto","family":"Palazzuoli","sequence":"first","affiliation":[{"name":"Cardiovascular Diseases Unit, Le Scotte Hospital University of Siena ,","place":["Italy"]},{"name":"National Institute for Cardiovascular Research , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2841-1429","authenticated-orcid":false,"given":"Gaetano","family":"Ruocco","sequence":"additional","affiliation":[{"name":"Veris Delli Ponti Hospital, ASL Lecce , Scorrano, Lecce ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Franceschi","sequence":"additional","affiliation":[{"name":"Department of Economics and Statistics, University of Siena , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Schir\u00f2","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases Unit, Le Scotte Hospital University of Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Petrini","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases Unit, Le Scotte Hospital University of Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Manetti","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases Unit, Le Scotte Hospital University of Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salzano","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, \u2018Federico II\u2019 University , Naples ,","place":["Italy"]},{"name":"Interdepartmental Center for Gender Medicine Research \u2018GENESIS\u2019 , Research center, Naples ,","place":["Italy"]},{"name":"Cardiac Unit, AORN A Cardarelli , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Severino","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome , Viale del Policlinico 155, Rome 00161 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8456-609X","authenticated-orcid":false,"given":"Marco","family":"Guazzi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Milano School of Medicine, San Paolo Hospital , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8845-7010","authenticated-orcid":false,"given":"Giulia","family":"Crisci","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Milano School of Medicine, San Paolo Hospital , Milano ,","place":["Italy"]},{"name":"Department of Cardiology and Jessa & Science, Jessa Hospital , Hasselt ,","place":["Belgium"]},{"name":"Faculty of Medicine and Life Sciences\/LCRC, Hasselt University , Diepenbeek ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barill\u00e0","sequence":"additional","affiliation":[{"name":"Health Sciences, UniCamillus-Saint Camillus International University , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Mariano","sequence":"additional","affiliation":[{"name":"Cardiology Department, Fondazione Policlinico Tor Vergata , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L","family":"Dini","sequence":"additional","affiliation":[{"name":"Department of Cardiology, San Luca Hospital, Istituto Auxologico Italiano, IRCCS , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariafrancesca","family":"Di Santo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Italian Society of Cardiology, Federico II University of Naples , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Perrone Filardi","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Italian Society of Cardiology, Federico II University of Naples , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Sorrentino","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Policlinico S Matteo Cardiology Department, , Pavia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1858-1152","authenticated-orcid":false,"given":"Stefano","family":"Ghio","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Policlinico S Matteo Cardiology Department, , Pavia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe M C","family":"Rosano","sequence":"additional","affiliation":[{"name":"Cardiovascular Translational Laboratory, IRCCS San Raffaele di Roma , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2026100604480730300_xvag230-B1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1161\/CIRCULATIONAHA.109.887570","article-title":"Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure","volume":"121","author":"Meyer","year":"2010","journal-title":"Circulation"},{"key":"2026100604480730300_xvag230-B2","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1161\/CIRCULATIONAHA.107.653584","article-title":"Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure","volume":"117","author":"Haddad","year":"2008","journal-title":"Circulation"},{"key":"2026100604480730300_xvag230-B3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ejhf.478","article-title":"Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology","volume":"18","author":"Harjola","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026100604480730300_xvag230-B4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ejhf.1029","article-title":"Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Gorter","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026100604480730300_xvag230-B5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s10741-022-10276-0","article-title":"Right heart failure in left heart disease: imaging, functional, and biochemical aspects of right ventricular dysfunction","volume":"28","author":"Ghio","year":"2022","journal-title":"Heart Fail Rev"},{"key":"2026100604480730300_xvag230-B6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ejhf.664","article-title":"Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction","volume":"19","author":"Ghio","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026100604480730300_xvag230-B7","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/ejhf.873","article-title":"Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction","volume":"19","author":"Bosch","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026100604480730300_xvag230-B8","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/ejhf.630","article-title":"Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"18","author":"Gorter","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026100604480730300_xvag230-B9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/ehf2.15095","article-title":"Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy","volume":"12","author":"Colombo","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026100604480730300_xvag230-B10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026100604480730300_xvag230-B11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jchf.2024.02.020","article-title":"Contemporary American and European guidelines for heart failure management: JACC: heart failure guideline comparison","volume":"12","author":"Ostrominski","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026100604480730300_xvag230-B12","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1093\/eurheartj\/ehac483","article-title":"Putting the puzzle together: SGLT2 inhibitors from prevention to treatment of heart failure","volume":"43","author":"Harrington","year":"2022","journal-title":"Eur Heart J"},{"key":"2026100604480730300_xvag230-B13","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"2026100604480730300_xvag230-B14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2459\/JCM.0000000000001623","article-title":"Right ventricular dysfunction in chronic heart failure: clinical laboratory and echocardiographic characteristics. (the RIVED-CHF registry)","volume":"25","author":"Palazzuoli","year":"2024","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026100604480730300_xvag230-B15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/eurjhf\/hfq045","article-title":"Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine","volume":"12","author":"Gheorghiade","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026100604480730300_xvag230-B16","doi-asserted-by":"publisher","first-page":"e578","DOI":"10.1161\/CIR.0000000000000560","article-title":"Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association","volume":"137","author":"Konstam","year":"2018","journal-title":"Circulation"},{"key":"2026100604480730300_xvag230-B17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026100604480730300_xvag230-B18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026100604480730300_xvag230-B19","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jcmg.2016.12.024","article-title":"RV Contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes","volume":"10","author":"Guazzi","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026100604480730300_xvag230-B20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.echo.2010.05.010","article-title":"Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography","volume":"23","author":"Rudski","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"key":"2026100604480730300_xvag230-B21","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jcmg.2020.12.011","article-title":"Prognostic implications of a novel algorithm to grade secondary tricuspid regurgitation","volume":"14","author":"Fortuni","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026100604480730300_xvag230-B22","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.jcmg.2023.08.011","article-title":"Echocardiographic reference ranges of global longitudinal strain for all cardiac chambers using guideline-directed dedicated views","volume":"16","author":"Nyberg","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026100604480730300_xvag230-B23","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026100604480730300_xvag230-B24","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1002\/ehf2.15408","article-title":"SGLT2 inhibitors for the prevention and treatment of heart failure: a scientific statement of the HFA and the HFAI","volume":"12","author":"Metra","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026100604480730300_xvag230-B25","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1002\/ehf2.15296","article-title":"Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: the DEFORM trial","volume":"12","author":"Huang","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026100604480730300_xvag230-B26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cardfail.2014.01.018","article-title":"Right ventricular function and prognosis in stable heart failure patients","volume":"20","author":"Murninkas","year":"2014","journal-title":"J Card Fail"},{"key":"2026100604480730300_xvag230-B27","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jacc.2018.12.076","article-title":"Anatomy, function, and dysfunction of the right ventricle: JACC state-of-the-art review","volume":"73","author":"Sanz","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026100604480730300_xvag230-B28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/ehjci\/jex133","article-title":"Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension","volume":"19","author":"Gorter","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026100604480730300_xvag230-B29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-022-01614-5","article-title":"Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling","volume":"21","author":"Wu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026100604480730300_xvag230-B30","doi-asserted-by":"publisher","first-page":"176875","DOI":"10.1016\/j.ejphar.2024.176875","article-title":"Dapagliflozin alleviates right heart failure by promoting collagen degradation by reducing ROS levels","volume":"981","author":"Liu","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"2026100604480730300_xvag230-B31","doi-asserted-by":"publisher","first-page":"176179","DOI":"10.1016\/j.ejphar.2023.176179","article-title":"The clinical outcomes of dapagliflozin in patients with acute heart failure: a randomized controlled trial (DAPA-RESPONSE-AHF)","volume":"961","author":"Emara","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"2026100604480730300_xvag230-B32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.122.059725","article-title":"Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial","volume":"146","author":"Kosiborod","year":"2022","journal-title":"Circulation"},{"key":"2026100604480730300_xvag230-B33","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamacardio.2024.1914","article-title":"Dapagliflozin and right ventricular-pulmonary vascular interaction in heart failure with preserved ejection fraction: a secondary analysis of a randomized clinical trial","volume":"9","author":"Reddy","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026100604480730300_xvag230-B34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/ehjci\/jeaa285","article-title":"Pressure-volume loop validation of TAPSE\/PASP for right ventricular arterial coupling in heart failure with pulmonary hypertension","volume":"22","author":"Schmeisser","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026100604480730300_xvag230-B35","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/ejechocard\/jep052","article-title":"Right ventricular function in patients with preserved and reduced ejection fraction heart failure","volume":"10","author":"Puwanant","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"2026100604480730300_xvag230-B36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pcad.2023.07.008","article-title":"Different right ventricular dysfunction and pulmonary coupling in acute heart failure according to the left ventricular ejection fraction","volume":"81","author":"Palazzuoli","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"2026100604480730300_xvag230-B37","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1253\/circj.CJ-20-0341","article-title":"Dapagliflozin influences ventricular hemodynamics and exercise-induced pulmonary hypertension in type 2 diabetes patients - A randomized controlled trial","volume":"84","author":"Kayano","year":"2020","journal-title":"Circ J"},{"key":"2026100604480730300_xvag230-B38","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026100604480730300_xvag230-B39","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jcmg.2024.05.014","article-title":"Dapagliflozin effects on cardiac deformation in heart failure and secondary clinical outcome","volume":"17","author":"Pastore","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026100604480730300_xvag230-B40","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12933-021-01390-8","article-title":"Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes","volume":"20","author":"Sarak","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026100604480730300_xvag230-B41","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1016\/j.jacc.2020.10.005","article-title":"Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction","volume":"76","author":"Omar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026100604480730300_xvag230-B42","doi-asserted-by":"publisher","first-page":"e040302","DOI":"10.1161\/JAHA.124.040302","article-title":"Safety and efficacy of dapagliflozin in patients with systemic right ventricular dysfunction: DAPA-SRV trial","volume":"14","author":"Albertini","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026100604480730300_xvag230-B43","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/ehf2.13871","article-title":"The first experience with sodium-glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure","volume":"9","author":"Egorova","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026100604480730300_xvag230-B44","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/ehf2.12850","article-title":"Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring","volume":"7","author":"Mullens","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026100604480730300_xvag230-B45","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.echo.2025.12.011","article-title":"Right ventricular function and ventricular-arterial coupling in HFpEF and HFmrEF treated with SGLT2 inhibitors: a multicenter echocardiographic analysis from the DISCOVER-SGLT2i registry","volume":"39","author":"Novo","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"key":"2026100604480730300_xvag230-B46","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/s0735-1097(98)00337-4","article-title":"Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure","volume":"32","author":"de Groote","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"2026100604480730300_xvag230-B47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijcard.2022.08.008","article-title":"The prognostic value of right ventricular ejection fraction by cardiovascular magnetic resonance in heart failure: a systematic review and meta-analysis","volume":"368","author":"Papanastasiou","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026100604480730300_xvag230-B48","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jacc.2017.01.051","article-title":"Pulmonary hypertension in heart failure: pathophysiology, pathobiology, and emerging clinical perspectives","volume":"69","author":"Guazzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026100604480730300_xvag230-B49","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","article-title":"Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction","volume":"137","author":"Fayyaz","year":"2018","journal-title":"Circulation"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag230\/70896086\/xvag230.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag230\/70896086\/xvag230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag230\/70896086\/xvag230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:48:15Z","timestamp":1791276495000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag230\/8778767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag230","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,27]]},"article-number":"xvag230"}}